Medra AI
- Company typePrivate
- Founded2023
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
Medra AI firmographics
Firmographics- Name
- Medra AI
- Legal name
- Medra
- Website
- https://medra.ai
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Medra AI industry classification
Industry- Product category
- AI-powered laboratory automation
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where Medra AI is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Medra AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales, Operations
Revenue model
- Biopharma R&D Partnerships & Deployments: Enterprise collaborations and co-development engagements with leading biopharma companies (Genentech, Addition Therapeutics, Cultivarium) integrating the Physical AI Scientist platform into their lab workflows. Likely multi-year, contract-based engagements.
- Medra Lab 001 (ML001) Data Foundry Service: Service offering that provides foundation model teams with wet-lab-generated experimental data and post-training loops without standing up their own labs. A platform-as-a-service style offering for AI biology model builders.
- Government & DARPA Funded Projects: Project-based revenue from DARPA-funded collaborations advancing capabilities to translate natural-language scientific goals into machine-executable experiments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise engagements (quote-based) |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
Medra AI product offering
Product offeringCore offering
Medra AI builds the Physical AI Scientist platform, which combines general-purpose robotics (Physical AI) with multi-modal LLM-based scientific reasoning (Scientific AI) to autonomously design, execute, and optimize life-sciences experiments on existing lab instruments. The platform runs as a closed-loop system that captures experimental data, detects errors with computer vision, and iteratively refines protocols. Medra also operates Medra Lab 001 (ML001), a 38,000-square-foot flagship autonomous laboratory in San Francisco, as both an in-house deployment and a data foundry for biopharma and foundation-model customers.
Product overview
Medra offers a single unified platform — the Continuous Science Platform (also marketed as the Physical AI Scientist Platform) — built from two tightly coupled modules: Physical AI (general-purpose robots running the proprietary Vision Language Lab Action model to execute protocols on existing lab instruments) and Scientific AI (a reasoning layer that ingests data, literature, and notebook entries to design and optimize experiments). On top of this platform, Medra launched the AI Experimentalist in June 2026 as a dedicated scientific reasoning layer that translates natural-language goals into machine-executable experiments, and operates Medra Lab 001 (ML001) — its flagship 38,000 sq ft autonomous laboratory in San Francisco — as the physical instantiation of the platform running 24/7 for partners in biopharma, academia, and government.
Differentiator
Problem solved
Functional benefit
Brands
- Medra Lab 001: Medra's flagship 38,000-square-foot autonomous science laboratory in San Francisco, housing hundreds of robots and covering the full design-make-test-analyze cycle; also referred to by abbreviation ML001.
- Continuous Science Platform
- Physical AI Scientist
- AI Experimentalist
Products and services
- Continuous Science Platform (Physical AI Scientist Platform) Medra's flagship unified platform that combines Physical AI (robotics) and Scientific AI (reasoning models) into a self-improving closed-loop system for autonomous life-sciences experimentation, executing end-to-end protocols across existing lab instruments and feeding results back into the model for continuous self-improvement. Targeted at biopharma R&D, AI foundation-model teams, government R&D, and academic labs.
- AI Experimentalist The dedicated scientific reasoning layer of the Physical AI Scientist Platform that translates natural-language scientific goals into machine-executable experiments. Operates in concert with Medra Lab 001 and is deployed in closed-beta projects across academia, biopharma, and government (including DARPA).
- Medra Lab 001 (ML001) Medra's flagship autonomous science laboratory in San Francisco, opened April 2026. A 38,000-square-foot facility housing hundreds of robots running 24/7, described as the largest autonomous lab in the United States. Operates as both a data foundry for AI foundation-model teams and a deployable blueprint for pharma-owned autonomous labs, covering the full design-make-test-analyze cycle.
Quantifiable outcome
- Reduced control variance by 10x (from 36.6% to 3.7%) in one month
- +5 more outcomes
Companies that use Medra AI
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
Medra AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability13 records
Feature8 records
Medra AI partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- DARPA (Defense Advanced Research Projects Agency)flagshipDARPA-funded project to advance capabilities for translating natural-language scientific goals into machine-executable experiments; conducted in concert with Medra Lab 001 (ML001). Announced alongside launch of the AI Experimentalist scientific reasoning layer.
- GenentechflagshipStrategic partnership to integrate Medra's AI and robotics into Genentech's lab systems for automated experiments and continuous learning across antibody discovery, protein engineering, gene editing, genomics, and cell biology. Highlighted in Medra Series A announcement and Genentech's own press communications as one of several AI partners (alongside NVIDIA, Recursion, AWS).
- Addition TherapeuticscorePartnership to automate Addition Therapeutics' RNA transfection workflow for its PRINT gene-editing platform. Medra's Physical AI executes experiments while Scientific AI reasons through results to optimize protocols. Delivered 10x control variance reduction, +35% transfection efficiency, 3x throughput, ~50 hours/week saved. Expansion planned into ELISA workflows integrated with electronic lab notebooks.
- CultivariumcorePartnership leveraging Medra's flexible robotics and AI platform to support Cultivarium's microbial discovery work; Cultivarium CEO Henry Lee cited Medra as 'a game changer' versus existing inflexible lab automation systems.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Medra AI competitors and assessment
Company assessmentDirect peers
- Strateos: Strateos provides cloud-based, robotic-driven lab automation for drug discovery, offering remote access to integrated lab workflows. It competes with Medra in enabling AI-driven biological experimentation through a software-controlled lab interface for biopharma customers.
- Ginkgo Bioworks: Ginkgo Bioworks combines large-scale automated lab infrastructure with AI/ML for synthetic biology and cell engineering. It is a direct competitor in automated biology R&D services and is pursuing a similar platform-as-a-service model for biology experimentation.
- Insitro: Insitro uses machine learning combined with high-throughput biology for therapeutic discovery, including automated lab infrastructure. It is a direct competitor for biopharma R&D budgets seeking AI-augmented experimentation and shares Medra's biopharma enterprise GTM motion.
- Emerald Cloud Lab: Emerald Cloud Lab operates a fully remote, automated life-sciences laboratory that scientists can access via software. It is a direct competitor in cloud-based, automated wet-lab execution and shares Medra's value proposition of running experiments without scientists physically present at the bench.
- Recursion Pharmaceuticals: Recursion combines high-throughput wet-lab experimentation with AI/ML for drug discovery, operating large-scale automated labs. It is the most directly comparable company to Medra in combining biology, robotics, and AI at scale, and is explicitly listed alongside Medra as a Genentech partner.
Emerging players
- LabGenius: LabGenius combines AI-driven closed-loop experimentation with robotics for protein engineering and antibody discovery. It is an emerging competitor in the AI + lab automation niche Medra targets, with overlap in antibody discovery and ML-driven protocol optimization.
- Benchling: Benchling provides a cloud-based life sciences R&D platform including electronic lab notebooks and workflow tools. It is adjacent to Medra — Medra's Scientific AI plugs into electronic lab notebooks including Benchling's — and is a potential integration partner as well as a competitor for biotech R&D software budgets.
- Arctoris: Arctoris operates a fully automated robotics-driven drug discovery lab offering remote experimental services to biotech and pharma clients. It overlaps with Medra's instrument-agnostic automation approach but with narrower scale and a stronger services-led rather than platform-led model.
Broad incumbents
- Automation Anywhere: Automation Anywhere is a broad incumbent in robotic process and intelligent automation with capabilities in vision, document understanding, and orchestrated workflows. While not life-science-specific, it represents the broader enterprise automation landscape where Medra's Physical AI capabilities could be benchmarked or extended.
Regional players
- Culture Biosciences: Culture Biosciences offers cloud-based, automated bioreactor lab services for bioprocess and synthetic biology applications. It is comparable in operating a remotely accessible automated lab but focuses on upstream bioprocess rather than Medra's broader life sciences R&D coverage.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medra AI social profiles
Digital presenceMedra AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medra AI leadership team
Management profileNumber of profiles
Profiles9 records
Medra AI subsidiaries and ownership
Company hierarchySubsidiaries1 record
Medra AI funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medra AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medra AI
What does Medra AI do?
Medra AI builds the Physical AI Scientist platform, which combines general-purpose robotics (Physical AI) with multi-modal LLM-based scientific reasoning (Scientific AI) to autonomously design, execute, and optimize life-sciences experiments on existing lab instruments. The platform runs as a closed-loop system that captures experimental data, detects errors with computer vision, and iteratively refines protocols. Medra also operates Medra Lab 001 (ML001), a 38,000-square-foot flagship autonomous laboratory in San Francisco, as both an in-house deployment and a data foundry for biopharma and foundation-model customers.
Is Medra AI a public or private company?
Medra AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medra AI founded?
Medra AI was founded in 2023. It employs 51 to 100 people.
Where is Medra AI based?
Medra AI is headquartered in San Francisco, United States, in the North America region.
How does Medra AI make money?
Three revenue lines are on record. Biopharma R&D Partnerships & Deployments are the primary driver. The others are medra Lab 001 (ML001) Data Foundry Service and government & DARPA Funded Projects.
Who are Medra AI's main competitors?
Direct peers on record are Strateos, Ginkgo Bioworks, Insitro, Emerald Cloud Lab and Recursion Pharmaceuticals. Emerging players are LabGenius, Benchling and Arctoris. Automation Anywhere is listed as a broad incumbent. Culture Biosciences is listed as a regional player.
Does Medra AI have an API?
No public API is recorded for Medra AI.
What industry is Medra AI in?
Medra AI's product category is AI-powered laboratory automation. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5417 and its SIC code is 8731.